Renaissance Capital logo

Aprea Therapeutics Priced, Nasdaq: APRE

Phase 3 biotech developing targeted therapies for cancer.

Industry: Health Care

Latest Trade: $4.45 -0.02 (-0.3%)

First Day Return: +36.7%

Return from IPO: -70.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains. Our lead product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. APR-246 has received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer, and we believe APR-246 will be a first-in-class therapy if approved by applicable regulators.
more less
IPO News for Aprea Therapeutics
more
IPO Data
IPO File Date 09/06/2019
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.7
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/02/2019
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.7
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Boston, MA
Founded 2002
Employees 14
Website www.aprea.com